Following the release of clinical study data, TransCode Therapeutics Inc. (NASDAQ: RNAZ) soared 38.53% to $1.51 in pre-market trading hours on the most recent check Wednesday.
What information did RNAZ share?
Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma were released today by TransCode Therapeutics (RNAZ).
- In a mouse model of pancreatic cancer, TransCode Therapeutics assessed the bioactivity of TTX-MC138, its primary treatment candidate.
- In the experiment, mice with human pancreatic tumors implanted in their pancreas received TTX-MC138 once every week for 10 weeks.
- By effectively suppressing its target, microRNA-10b (miR-10b), as evaluated by qRT-PCR, a widely used technique for determining gene expression, the medication showed a pharmacodynamic response.
- A potential substitute biomarker of treatment effectiveness, serum miR-10b, was down-regulated by TTX-MC138 in this investigation.
- In 40% of the rats given TTX-MC138 treatment, full responses—defined as total disease regression and sustained survival without recurrence—occurred.
- More research is being done to pinpoint the ideal dosage and therapeutic window for pancreatic cancer.
How encouraging are the results for RNAZ?
The therapeutic usefulness of TTX-MC138 may now also be extended to pancreatic cancer as a result of these recent discoveries. The efficacy of TTX-MC138 to induce durable regression of metastatic breast cancer in murine models had already been demonstrated, so RNAZ’s next step was to assess the applicability of its therapeutic approach in a pancreatic cancer model with an eye toward evaluating other solid tumor types that express miR-10b.
The results of this pancreatic cancer research, as with earlier ones, justify the development of TTX-MC138 in the clinic. These preclinical findings provide RNAZ further assurance that TTX-MC138 has the potential to develop into a cutting-edge, first-in-class therapeutic strategy for treating advanced solid tumors, which may eventually lead to better clinical results for patients.
How will RNAZ move forward?
TransCode Therapeutics (RNAZ) is taking a key step in the preclinical development process by demonstrating effective therapy utilizing its first-in-class RNA-targeted therapeutic candidate in a number of solid tumor models, greatly de-risking its strategy. For its planned Phase 0 first-in-human (FIH) clinical study using TTX-MC138 in cancer patients with advanced solid tumors, as RNAZ has previously mentioned, the company is on schedule to file an exploratory Investigational New Drug Application (eIND) this year.